The PREVAIL study: Primary and non-visceral/visceral disease subgroup results for enzalutamide-treated men with metastatic castration-resistant prostate cancer.

Fred Saad, Christopher P. Evans, Celestia S Higano, Thomas Keane, Gerald Andriole, Peter Iversen, Kurt Miller, Choung-Soo Kim, Go Kimura, Andrew J. Armstrong, Cora N Sternberg, Yohann Loriot, Johann de Bono, Sara Noonberg, Harry H. Mansbach, Suman Bhattacharya, Frank Perabo, Tomasz M. Beer, Bertrand Tombal

    Original languageEnglish
    Article numberMP16.09
    Issue number4
    Pages (from-to)S1-146
    Publication statusPublished - 2014

    Cite this